Aptose Announces Receipt of Deficiency Notice from Nasdaq
19. Juli 2024 17:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the Fourth Quarter and Full Year 2022
23. März 2023 16:44 ET
|
Aptose Biosciences, Inc.
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML...
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
07. Dezember 2022 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
18. Oktober 2022 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase...
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
14. September 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
13. September 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability
12. September 2022 07:30 ET
|
Aptose Biosciences, Inc.
– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239...
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
02. Mai 2022 16:10 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Participate in Two Biotech Events in January 2022
29. Dezember 2021 07:30 ET
|
Aptose Biosciences, Inc.
— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc....
Aptose Expands Senior Leadership Team
25. Oktober 2021 08:00 ET
|
Aptose Biosciences, Inc.
Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...